Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has maintained a 'Buy' rating on Marinus Pharma (NASDAQ:MRNS), but lowered the price target from $42 to $32.

August 11, 2023 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Marinus Pharma's price target has been lowered from $42 to $32 by Truist Securities, though the 'Buy' rating is maintained.
The news is directly about Marinus Pharma and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the short-term upside potential of the stock. However, the impact on the stock price is uncertain as the 'Buy' rating might still attract investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100